Transmembrane protein with unknown function 16A overexpression promotes glioma formation through the nuclear factor-κB signaling pathway

Molecular Medicine Reports

Volumn 9, Issue 3, 2014, Pages 1068-1074

  Liu, Jun ^a   Liu, Yu ^a   Ren, Yingang ^a   Kang, Li ^a   Zhang, Lihua ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Calcium activated chloride channels; Glioma; Nuclear factor B; Transmembrane protein with unknown function 16A

Indexed keywords

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHLORIDE CHANNELS; FEMALE; GLIOMA; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM PROTEINS; NF-KAPPA B; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84893848153     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.1888     Document Type: Article

References (54)

1. Stühmer W, Alves F, Hartung F, Zientkowska M and Pardo LA: Potassium channels as tumour markers. FEBS Lett 580: 2850-2852, 2006.
2. Lastraioli E, Taddei A, Messerini L, et al: hERG1 channels in human esophagus: evidence for their aberrant expression in the malignant progression of Barrett's esophagus. J Cell Physiol 209: 398-404, 2006.
3. Masi A, Becchetti A, Restano-Cassulini R, et al: hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer 93: 781-792, 2005.
4. Panner A and Wurster RD: T-type calcium channels and tumor proliferation. Cell Calcium 40: 253-259, 2006.
5. Diss JK, Stewart D, Pani F, et al: A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo. Prostate Cancer Prostatic Dis 8: 266-273, 2005.
6. Fraser SP, Diss JK, Chioni AM, et al: Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res 11: 5381-5389, 2005.
7. Furst J, Gschwentner M, Ritter M, et al: Molecular and functional aspects of anionic channels activated during regulatory volume decrease in mammalian cells. Pfl ugers Arch 444: 1-25, 2002.
8. Ferrera L, Caputo A and Galietta LJ: TMEM16A protein: a new identity for Ca(2+)-dependent Cl-channels. Physiology (Bethesda) 25: 357-363, 2010.
9. Hartzell C, Putzier I and Arreola J: Calcium-activated chloride channels. Annu Rev Physiol 67: 719-758, 2005.
10. Caputo A, Caci E, Ferrera L, et al: TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 322: 590-594, 2008.
11. Yang YD, Cho H, Koo JY, et al: TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 455: 1210-1215, 2008.
12. Schroeder BC, Cheng T, Jan YN and Jan LY: Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell 134: 1019-1029, 2008.
13. Rock JR, O'Neal WK, Gabriel SE, et al: Transmembrane protein 16A (TMEM16A) is a Ca2+-regulated Cl-secretory channel in mouse airways. J Biol Chem 284: 14875-14880, 2009.
14. Huang F, Rock JR, Harfe BD, et al: Studies on expression and function of the TMEM16A calcium-activated chloride channel. Proc Natl Acad Sci USA 106: 21413-21418, 2009.
15. Hwang SJ, Blair PJ, Britton FC, et al: Expression of anoctamin 1/TMEM16A by interstitial cells of Cajal is fundamental for slow wave activity in gastrointestinal muscles. J Physiol 587: 4887-4904, 2009.
16. Romanenko VG, Catalán MA, Brown DA, et al: Tmem16A encodes the Ca2+-activated Cl-channel in mouse submandibular salivary gland acinar cells. J Biol Chem 285: 12990-13001, 2010.
17. Elble RC and Pauli BU: Tumor suppression by a proapoptotic calcium-activated chloride channel in mammary epithelium. J Biol Chem 276: 40510-40517, 2001.
18. Spitzner M, Martins JR, Soria RB, et al: Eag1 and Bestrophin 1 are up-regulated in fast-growing colonic cancer cells. J Biol Chem 283: 7421-7428, 2008.
19. Katoh M and Katoh M: FLJ10261 gene, located within the CCND1-EMS1 locus on human chromosome 11q13, encodes the eight-transmembrane protein homologous to C12orf3, C11orf25 and FLJ34272 gene products. Int J Oncol 22: 1375-1381, 2003.
20. Akervall JA, Jin Y, Wennerberg JP, et al: Chromosomal abnormalities involving 11q13 are associated with poor prognosis in patients with squamous cell carcinoma of the head and neck. Cancer 76: 853-859, 1995.
21. Schwab M: Amplification of oncogenes in human cancer cells. Bioessays 20: 473-479, 1998.
22. Carles A, Millon R, Cromer A, et al: Head and neck squamous cell carcinoma transcriptome analysis by comprehensive validated differential display. Oncogene 25: 1821-1831, 2006.
23. Espinosa I, Lee CH, Kim MK, et al: A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 32: 210-218, 2008.
24. Kashyap MK, Marimuthu A, Kishore CJ, et al: Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers. Cancer Biol Ther 8: 36-46, 2009.
25. Yang H, Huang LY, Zeng DY, et al: Decrease of intracellular chloride concentration promotes endothelial cell infl ammation by activating nuclear factor-kappaB pathway. Hypertension 60: 1287-1293, 2012.
26. Chen J, Fok KL, Chen H, et al: Cryptorchidism-induced CFTR down-regulation results in disruption of testicular tight junctions through up-regulation of NF-κB/COX-2/PGE2. Hum Reprod 27: 2585-2597, 2012.
27. He G, Ma Y, Chou SY, et al: Role of CLIC4 in the host innate responses to bacterial lipopolysaccharide. Eur J Immunol 41: 1221-1230, 2011.
28. Sheridan GK, Pickering M, Twomey C, et al: NF-kappaB activity in distinct neural subtypes of the rat hippocampus: Infl uence of time and GABA antagonism in acute slice preparations. Learn Mem 14: 525-532, 2007.
29. Miller FJ, Jr, Filali M, Huss GJ, et al: Cytokine activation of nuclear factor kappa B in vascular smooth muscle cells requires signaling endosomes containing Nox1 and ClC-3. Circ Res 101: 663-671, 2007.
30. Laver T, Nozell S and Benveniste EN: The NF-κB signaling pathway in GBMs: implications for apoptotic and inflammatory responses and exploitation for therapy. In: CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches. Van Meir EG (ed). Vol 2. Humana Press (Springer), New York, NY, pp1011-1036, 2009
31. Gilmore TD: Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25: 6680-6684, 2006.
32. Perkins ND: The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci 25: 434-440, 2000.
33. Perkins ND and Gilmore TD: Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ 13: 759-772, 2006.
34. Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109, 2007.
35. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
36. Lee CH, Jeon YT, Kim SH and Song YS: NF-kappaB as a potential molecular target for cancer therapy. Biofactors 29: 19-35, 2007.
37. Sethi G, Sung B and Aggarwal BB: Nuclear factor-kappaB activation: from bench to bedside. Experiment Biol Med (Maywood) 233: 21-31, 2008.
38. Van Waes C: Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13: 1076-1082, 2007.
39. Bauvois B: New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 1825: 29-36, 2012.
40. Veeravalli KK and Rao JS: MMP-9 and uPAR regulated glioma cell migration. Cell Adh Migr 6: 509-512, 2012.
41. Kesanakurti D, Chetty C, Rajasekhar Maddirela D, Gujrati M and Rao JS: Functional cooperativity by direct interaction between PAK4 and MMP-2 in the regulation of anoikis resistance, migration and invasion in glioma. Cell Death Dis 3: e445, 2012.
42. Habela CW, Ernest NJ, Swindall AF and Sontheimer H: Chloride accumulation drives volume dynamics underlying cell proliferation and migration. J Neurophysiol 101: 750-757, 2009.
43. Habela CW, Olsen ML and Sontheimer H: ClC3 is a critical regulator of the cell cycle in normal and malignant glial cells. J Neurosci 28: 9205-9217, 2008.
44. Kunzelmann K, Kongsuphol P, Aldehni F, et al: Bestrophin and TMEM16-Ca(2+) activated Cl(-) channels with different functions. Cell Calcium 46: 233-241, 2009.
45. Ayoub C, Wasylyk C, Li Y, et al: ANO1 amplification and expression in HNSCC with a high propensity for future distant metastasis and its functions in HNSCC cell lines. Br J Cancer 103: 715-726, 2010.
46. Duvvuri U, Shiwarski DJ, Xiao D, et al: TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res 72: 3270-3281, 2012.
47. Simon S, Grabellus F, Ferrera L, et al: DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors. Cancer Res 73: 3661-3670, 2013.
48. Mazzone A, Eisenman ST, Strege PR, et al: Inhibition of cell proliferation by a selective inhibitor of the Ca(2+)-activated Cl(-) channel, Ano1. Biochem Biophys Res Commun 427: 248-253, 2012.
49. Liu W, Lu M, Liu B, Huang Y and Wang K: Inhibition of Ca(2+)-activated Cl(-) channel ANO1/TMEM16A expression suppresses tumor growth and invasiveness in human prostate carcinoma. Cancer Lett 326: 41-51, 2012.
50. Abdullah JM, Ahmad F, Ahmad KA, et al: Molecular genetic analysis of BAX and Cyclin D1 genes in patients with malignant glioma. Neurol Res 29: 239-242, 2007.
51. Arato-Ohshima T and Sawa H: Over-expression of cyclin D1 induces glioma invasion by increasing matrix metalloproteinase activity and cell motility. Int J Cancer 83: 387-392, 1999.
52. Zhang X, Zhao M, Huang AY, et al: The effect of cyclin D expression on cell proliferation in human gliomas. J Clin Neurosci 12: 166-168, 2005.
53. Liao DJ, Thakur A, Wu J, Biliran H and Sarkar FH: Perspectives on c-Myc, cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. Crit Rev Oncogen 13: 93-158, 2007.
54. Robson S, Pelengaris S and Khan M: c-Myc and downstream targets in the pathogenesis and treatment of cancer. Recent Pat Anticancer Drug Discov 1: 305-326, 2006.